

Nicolas L Dzamko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6760036/publications.pdf>

Version: 2024-02-01

56
papers

4,162
citations

136950

32
h-index

175258

52
g-index

56
all docs

56
docs citations

56
times ranked

5043
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. <i>Nature Chemical Biology</i> , 2011, 7, 203-205.	8.0	380
2	14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. <i>Biochemical Journal</i> , 2010, 430, 393-404.	3.7	355
3	Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. <i>Biochemical Journal</i> , 2010, 430, 405-413.	3.7	355
4	CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. <i>Nature Medicine</i> , 2006, 12, 541-548.	30.7	250
5	Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. <i>Acta Neuropathologica</i> , 2017, 133, 303-319.	7.7	200
6	Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. <i>Biochemical Journal</i> , 2009, 424, 47-60.	3.7	186
7	The I κ B Kinase Family Phosphorylates the Parkinson's Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling. <i>PLoS ONE</i> , 2012, 7, e39132.	2.5	183
8	Inflammation is genetically implicated in Parkinson's disease. <i>Neuroscience</i> , 2015, 302, 89-102.	2.3	182
9	AMPK β 1 Deletion Reduces Appetite, Preventing Obesity and Hepatic Insulin Resistance. <i>Journal of Biological Chemistry</i> , 2010, 285, 115-122.	3.4	154
10	Whole Body Deletion of AMP-activated Protein Kinase β 2 Reduces Muscle AMPK Activity and Exercise Capacity. <i>Journal of Biological Chemistry</i> , 2010, 285, 37198-37209.	3.4	145
11	Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. <i>Diabetologia</i> , 2004, 47, 1306-1313.	6.3	126
12	AMPK-independent pathways regulate skeletal muscle fatty acid oxidation. <i>Journal of Physiology</i> , 2008, 586, 5819-5831.	2.9	121
13	Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity. <i>Hepatology</i> , 2010, 52, 1632-1642.	7.3	89
14	LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. <i>Movement Disorders</i> , 2019, 34, 406-415.	3.9	83
15	Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. <i>Scientific Reports</i> , 2018, 8, 15446.	3.3	82
16	Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. <i>Movement Disorders</i> , 2016, 31, 889-897.	3.9	76
17	Autophagy activation promotes clearance of α -synuclein inclusions in fibril-seeded human neural cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 14241-14256.	3.4	76
18	AMPK-dependent hormonal regulation of whole-body energy metabolism. <i>Acta Physiologica</i> , 2009, 196, 115-127.	3.8	75

#	ARTICLE	IF	CITATIONS
19	Parkinson's disease-implicated kinases in the brain; insights into disease pathogenesis. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 57.	2.9	73
20	Metformin Prevents the Development of Acute Lipid-Induced Insulin Resistance in the Rat Through Altered Hepatic Signaling Mechanisms. <i>Diabetes</i> , 2004, 53, 3258-3266.	0.6	71
21	Contraction-induced skeletal muscle FAT/CD36 trafficking and FA uptake is AMPK independent. <i>Journal of Lipid Research</i> , 2011, 52, 699-711.	4.2	67
22	Parkinson's progression prediction using machine learning and serum cytokines. <i>Npj Parkinson's Disease</i> , 2019, 5, 14.	5.3	63
23	Rosiglitazone Treatment Enhances Acute AMP-Activated Protein Kinase-Mediated Muscle and Adipose Tissue Glucose Uptake in High-Fat-Fed Rats. <i>Diabetes</i> , 2006, 55, 2797-2804.	0.6	59
24	LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, Volume 8, 177-189.	1.2	49
25	Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease. <i>Drugs</i> , 2019, 79, 1037-1051.	10.9	48
26	Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 758-767.	5.5	45
27	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2013, 3, 145-152.	2.8	44
28	LRRK2 and the Immune System. <i>Advances in Neurobiology</i> , 2017, 14, 123-143.	1.8	42
29	LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. <i>Movement Disorders</i> , 2017, 32, 423-432.	3.9	39
30	An emerging role for LRRK2 in the immune system. <i>Biochemical Society Transactions</i> , 2012, 40, 1134-1139.	3.4	36
31	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. <i>Brain</i> , 2018, 141, 486-495.	7.6	36
32	Leucine Rich Repeat Kinase 2 and Innate Immunity. <i>Frontiers in Neuroscience</i> , 2020, 14, 193.	2.8	36
33	Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. <i>Scientific Reports</i> , 2016, 6, 31391.	3.3	32
34	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. <i>European Journal of Medicinal Chemistry</i> , 2015, 95, 29-34.	5.5	31
35	Immune responses in the Parkinson's disease brain. <i>Neurobiology of Disease</i> , 2022, 168, 105700.	4.4	30
36	DNA extraction from fresh-frozen and formalin-fixed, paraffinembedded human brain tissue. <i>Neuroscience Bulletin</i> , 2013, 29, 649-654.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Lipid pathway dysfunction is prevalent in patients with Parkinson's disease. <i>Brain</i> , 2022, 145, 3472-3487.	7.6	25
38	Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity. <i>Movement Disorders</i> , 2021, 36, 2719-2730.	3.9	22
39	Mannose 6-Phosphate Receptor Is Reduced in α -Synuclein Overexpressing Models of Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0160501.	2.5	19
40	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. <i>Npj Parkinson's Disease</i> , 2022, 8, 34.	5.3	18
41	Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1451-1455.	3.9	17
42	Single-Molecule Counting Coupled to Rapid Amplification Enables Detection of α -Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 11874-11883.	13.8	17
43	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. <i>Neurobiology of Disease</i> , 2018, 120, 76-87.	4.4	16
44	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1761-1772.	2.8	15
45	WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	3.7	13
46	Single-Molecule Counting Coupled to Rapid Amplification Enables Detection of α -Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients. <i>Angewandte Chemie</i> , 2021, 133, 11981-11990.	2.0	11
47	Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson's Disease Patient Monocytes and Inversely Correlates with Motor Severity. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1157-1165.	2.8	11
48	LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. <i>Neurobiology of Disease</i> , 2020, 144, 105049.	4.4	10
49	Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. <i>Neurobiology of Disease</i> , 2021, 157, 105426.	4.4	7
50	A small molecule toll-like receptor antagonist rescues α -synuclein fibril pathology. <i>Journal of Biological Chemistry</i> , 2022, 298, 102260.	3.4	6
51	Unlocking the secrets of LRRK2 function with selective kinase inhibitors. <i>Future Neurology</i> , 2013, 8, 347-357.	0.5	4
52	Sex-specific lipid dysregulation in the <i>Abca7</i> knockout mouse brain. <i>Brain Communications</i> , 2022, 4, .	3.3	4
53	Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. <i>Bio-protocol</i> , 2020, 10, e3572.	0.4	2
54	Investigating lymphocyte populations in patients with Parkinson's disease. <i>Annals of Translational Medicine</i> , 2020, 8, 276-276.	1.7	1

#	ARTICLE	IF	CITATIONS
55	LRRK2 mutations, regulation and 14-3-3 protein interaction: implications for Parkinson's disease. Future Neurology, 2011, 6, 5-8.	0.5	0
56	Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of β -Synuclein Autoantibodies in Human Plasma. Bioconjugate Chemistry, 2022, , .	3.6	0